medicalxpress.com· Medical Xpress - Cancer·· 1 day agoPickScore97
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results
In brief
Dana-Farber Cancer Institute reported results from the phase 3 DeLLphi-305 trial: tarlatamab plus durvalumab as first-line maintenance extended median overall survival by more than eight months, to 21.1 months, in extensive-stage small cell lung cancer compared with durvalumab alone.
Why it matters
DeLLphi-305 provides randomized controlled data in 563 patients quantifying OS, PFS and death risk of the combination versus monotherapy for first-line maintenance.
Source: medicalxpress.com · medicalxpress.com